Home energy technology company Enphase (NASDAQ:ENPH) announced better-than-expected revenue in Q3 CY2025, with sales up 7.8% year on year to $410.4 million. On the other hand, next quarter’s revenue guidance of $330 million was less impressive, coming in 11.9% below analysts’ estimates. Its non-GAAP profit of $0.90 per share was 37.2% above analysts’ consensus estimates….
Computer processor maker Intel (NASDAQ:INTC) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 2.8% year on year to $13.65 billion. On the other hand, next quarter’s revenue guidance of $13.3 billion was less impressive, coming in 0.8% below analysts’ estimates. Its non-GAAP profit of $0.08 per share was significantly above analysts’ consensus…
The stock market flashed a key technical signal that suggests a pullback from all-time highs is on the way. That’s according to Jonathan Krinsky, the managing director and chief market technician at BTIG, who thinks the S&P 500 is bound for a 5% pullback soon. The benchmark index just broke through a technical resistance level…
Not only does Airbnb want to be the “everything app” — where users can book literally everything, from accommodations to experiences and services — it also wants to do the booking for you. Brian Chesky, cofounder and CEO of Airbnb, laid out his vision for the travel app’s AI-powered future during the company’s second-quarter earnings…
On-demand food delivery service DoorDash (NYSE:DASH) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 24.9% year on year to $3.28 billion. Its GAAP profit of $0.65 per share was 49.5% above analysts’ consensus estimates. Is now the time to buy DoorDash? Find out in our full research report. Revenue: $3.28 billion vs…
Newspaper and digital media company The New York Times (NYSE:NYT) reported Q2 CY2025 results exceeding the market’s revenue expectations , with sales up 9.7% year on year to $685.9 million. Its non-GAAP profit of $0.58 per share was 12.7% above analysts’ consensus estimates. Is now the time to buy The New York Times? Find out…
Genetic testing company Myriad Genetics (NASDAQ:MYGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, but sales were flat year on year at $213.1 million. The company’s full-year revenue guidance of $823 million at the midpoint came in 1.5% above analysts’ estimates. Its non-GAAP profit of $0.05 per share was significantly above analysts’ consensus…